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Abstract
Background: Despite a growing body of evidence reporting the deleterious mechanical and oncological
complications of biopsy of hepatic malignancy, a small but significant number of patients undergo the
procedure prior to specialist surgical referral. Biopsy has been shown to result in poorer longterm survival
following resection and advances in modern imaging modalities provide equivalent, or better, diagnostic
accuracy.
Methods: The literature relating to needle-tract seeding of primary and secondary liver cancers was
reviewed. MEDLINE, EMBASE and the Cochrane Library were searched for case reports and series
relating to the oncological complications of biopsy of liver malignancies. Current non-invasive diagnostic
modalities are reviewed and their diagnostic accuracy presented.
Results: Biopsy of malignant liver lesions has been shown to result in poorer longterm survival following
resection and does not confer any diagnostic advantage over a combination of non-invasive imaging
techniques and serum tumour markers.
Conclusions: Given that chemotherapeutic advances now often permit downstaging and subsequent
resection of ‘unresectable’ disease, the time has come to abandon biopsy of solid lesions outside the
setting of a specialist multi-disciplinary team meeting (MDT).
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Introduction
Liver resection is now well established as a safe and efficacious
treatment associated with minimal mortality and longterm sur-
vival benefits in correctly selected primary and secondary hepatic
malignancies.1 Advances in chemotherapeutic agents, operative
techniques and surgical technology have combined with better
understanding of tumour biology and greater use of radiological
interventions, such as portal vein embolization, to allow a con-
stant widening of the criteria that define the boundaries for resec-
tion.2 An effective diagnostic paradigm is essential in assessing
resectable solid liver lesions and, despite growing evidence dem-
onstrating its detrimental effects,3 which include the seeding of
1000–100 000 cells along each needle tract,4 biopsy is still being
used in the diagnostic pathway for such lesions. Sadly, a significant
number of patients with potentially resectable liver disease still
undergo biopsy of the lesion prior to referral to a hepatobiliary
surgical unit. Although unusual, tumour seeding along the biopsy
needle tract can convert a potentially curable case to one with
disseminated peritoneal disease, whilst adding virtually nothing to
the diagnostic pathway.
A combination of modern imaging techniques, the use of
serum tumour markers and clinical acumen negates a require-
ment for biopsy in almost all cases. Given its well-documented
mechanical and oncological complications, the time has come for
biopsy to be dropped from preoperative assessment.
A review of the potential dangers of biopsy along with the
non-invasive techniques available for the characterization of solid
hepatic lesions is presented.
Materials and methods
MEDLINE, EMBASE and Cochrane Library searches were per-
formed to identify reported cases and case series of needle tract
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seeding following biopsy of solid liver tumours. Reports of
seeding after biopsy of colorectal liver metastasis and hepatocel-
lular carcinoma (HCC) were discovered. These reports were
reviewed and summarized along with the evidence for potential
mechanical complications of liver biopsy; these data are presented
in combination with information on the current utility of modern
imaging techniques and serum tumour markers.
Mechanical complications of liver biopsy
Although it is often considered a relatively benign and straight-
forward procedure, liver biopsy is not without risk of mechanical
complication. The British Society of Gastroenterology published
guidance on the use of liver biopsy in 1999.5 Overall mortality
associated with biopsy was quoted as being 19% at 3 months6 and
was mainly related to the underlying diagnosis leading to biopsy.
Mortality that is specifically related to the biopsy procedure is
mainly caused by haemorrhage5 and rates vary between institu-
tions, with an apparent relationship to volume of practice.
Haemorrhage-related mortality in the specialist setting of the
Mayo Clinic was 0.11%,7 but rose to up to three times higher
(0.33%) in an audit of UK district general hospitals.6
The UK guidelines also seek to quantify the morbidity associ-
ated with liver biopsy and suggest an incidence of minor compli-
cations of 5.9%.8 Pain was the most commonly cited complication
and was reported in 30% of cases.6 Significant haemorrhage,
resulting in a drop in haemoglobin of >2 g/dl occurs in up to 0.5%
of procedures,9 with up to 23% having intrahepatic or subcapsular
haematomas, detectable by ultrasound at 24 h post-biopsy.10
Haemobiliamaybe expected in0.05%of cases5 andother signifi-
cant complications, including bile leak, sepsis, pancreatitis, local
infections or pneumothorax, in 0.23%.11–13 These seemingly small
risks must be considered in the light of studies that suggest a
diagnostic accuracy for fine-needle aspiration biopsy of 69.0–
80.6% and for core biopsy of 86–88% and an overall accuracy of
90.7%14,15 using both techniques combined. Similar and better re-
sults are achievable by non-invasive techniques, as detailed below.
Oncological complications of biopsy of
colorectal liver metastases
Four case reports detailing a total of six patients,16–19 along with
three small case series of five,20 seven21 and 173 patients have
described cases of tumour dissemination following biopsy of col-
orectal liver metastasis, whether performed surgically or percuta-
neously (Table 1).
The reported incidence of seeding in the three case series ranges
from 10% in the smallest series of five patients20 to 19% in the
largest series of 17.3
The largest series,3 which also had the longest follow-up
(minimum of 4 years), described a total of 598 patients who had
undergone liver resection with curative intent for colorectal liver
metastasis. Ninety (15.1%) of these 598 patients had undergone
preoperative biopsy, of which 50 had been performed at the time
of a previous laparotomy and 40 by a percutaneous technique
under radiological guidance. Despite attempts to resect deposits
within the needle tract with a macroscopic radical clearance of
tumour, a significant risk to longterm survival was observed, with
a 4-year survival rate of 32.5% in the biopsy group vs. 46.7% in the
control group. Analysis of the two groups showed that preopera-
tive biopsy was an independent predictor of survival following
resection of colorectal liver metastasis (P = 0.001) (Fig. 1).
In the 508 patients who did not undergo preoperative biopsy,
seven benign lesions were encountered. In one patient, a clearly
benign haemangioma was identified at laparotomy and was not
Table 1 Summary of published literature relating to the complications of biopsy of colorectal liver metastases
Authors Year Design n Findings
Al-Leswas et al.16 2008 Case report 2 2 cases of implantation
Jones et al.3 2005 Retrospective review 17 19% seeding rate; poorer longterm survival after biopsy
Rodgers et al.21 2003 Retrospective review 7 16% risk of seeding irrespective of route of biopsy
Metcalfe et al.18 2004 Case report 1 Biopsy added nothing to diagnostic pathway
Ohlsson et al.20 2002 Case series 5 10% seeding rate
Scheele & Altendorf-Hofmann19 1990 Case report 2 Seeding following biopsy of resectable lesion
Ferrucci et al.17 1979 Case report 1 First documented case of tract seeding
Figure 1 Kaplan–Meier survival curve comparing survival after liver
resection in patients who underwent biopsy of suspected colorectal
metastases (Group 1, biopsy) and those who did not (Group 2,
no biopsy) (Jones et al. 20053)
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resected, leaving a total of six patients (1.2% of the overall group)
to undergo resection of what were ultimately proven to be benign
lesions.
Similar effects with tumour dissemination have been shown in
smaller case series. A study of 43 patients who underwent preop-
erative biopsy revealed a seeding rate of 16%21 and a further study
of 51 patients demonstrated a seeding rate of 10%.20
Given the clarity of the message that biopsy can lead to dissemi-
nation and that such dissemination has a deleterious effect on
longterm survival, it is indeed depressing that although the first
case report was filed as long ago as 1979, a further two cases were
reported as recently as 2008.16
Oncological complications of biopsy in
suspected hepatocellular carcinoma
Similar effects of tumour dissemination both within the liver and
elsewhere have been reported following biopsies in HCC, with
reported seeding rates of 1.6–5.1%22–29 and sites of extrahepatic
spread including the peritoneum, ribs, muscle and skin. A system-
atic review of eight previous case reports and series suggests an
overall seeding rate of 2.7%30 (Table 2).
Furthermore, at least one study has again identified preopera-
tive biopsy as an independent predictor of poor outcome with an
observed rate of peritoneal recurrence of 12.5% following biopsy
vs. 1.6% with no biopsy. Five-year disease-free survival has also
been deleteriously affected, with reported rates of 24% following
biopsy and 52% without biopsy.31
Despite these reported cases, specialist agreement on abandon-
ing biopsy for HCC is less universal and, indeed, several authors
advocate its use. The majority of controversy surrounds two small
subsets of patients, the first of which demonstrate small nodules
(1–2 cm) against a background of cirrhosis and the second
of which exhibit larger tumours which fall outside transplant
criteria.
In the case of small lesions, which, with current imaging reso-
lution, are impossible to distinguish from regenerative nodules,
some enthusiasts have advocated biopsy on the basis of a rela-
tively low seeding rate.32 It is widely accepted, however, that
HCCs > 2 cm in size can be reliably identified by their imaging
characteristics of hypervascularity in an arterial phase with
washout in the early or delayed venous phase on either com-
puted tomography (CT) or magnetic resonance imaging
(MRI).33,34 Interval surveillance scanning therefore remains a
reasonable alternative to biopsy in patients with small, indeter-
minate nodules and would seem particularly prudent, given that
the risk of seeding following biopsy is not related to the size of
the lesion.35
For larger tumours that fall outside current transplant criteria
there is emerging evidence that certain biological features on
biopsy (such as low grade, a high degree of differentiation or lack
of vascular invasion36) can suggest a good prognosis, which may
justify an expansion of transplant criteria. One- and 3-year sur-
vival rates of 84.2% and 67.4%, respectively, have been reported
for tumours that fall outwith the Milan criteria but which are
without vascular invasion.37 However, these potential advantages
must be balanced against data that suggest that both the degree of
differentiation and the presence of vascular invasion can be sig-
nificantly underestimated on a needle core biopsy compared with
the explanted specimen.38
These tumours are, by definition, otherwise untransplantable
and the degree of underlying cirrhosis usually precludes resection.
In such cases, the patient’s outlook is bleak and therefore biopsy is
justified39 if it is carried out with a view to selecting patients for a
therapy that would otherwise be unavailable and is performed
within the setting of a clinical trial.
Non-invasive diagnosis of metastatic
malignancy
Recent advances in imaging technologies coupled with the infor-
mation provided by serum tumour markers mean that the major-
ity of resectable liver lesions can be accurately characterized and a
definitive diagnosis reached without the need for biopsy.40,41 Such
an approach carries the obvious advantage of avoiding the poten-
tial for biopsy complications, but it does require a paradigm shift
in the approach to diagnosis and, particularly, in the approach to
treatment. Malignant lesions, especially, can be identified with
Table 2 Summary of published literature relating to the complications of biopsy of hepatocellular carcinoma
Authors Year Design n Findings
Qua et al.26 2008 Case report 1 Seeding after biopsy
Liu et al.25 2007 Case report 5 2 of 5 converted from potentially curative to palliative by seeding
Kosugi et al.24 2004 Case series 6 1.6% seeding rate
Durand et al.22 2001 Retrospective review 2 1.6% seeding rate
Kim et al.23 2000 Case series 7 3.4% seeding rate
Takamori et al.27 2000 Case report 3 5.1% seeding rate
Chapoutot et al.28 1999 Case report 4 2.7% seeding rate
Huang et al.29 1996 Case series 9 2.1% seeding rate
Silva et al.30 2008 Review 26 2.7% overall seeding rate
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sufficient accuracy to justify resection without a proven tissue
diagnosis and, as a result of the low morbidity and mortality
now associated with such procedures, their advantages greatly
outweigh those of biopsy, given its risk for oncological
complications.1
Imaging remains themainstay of diagnosis,with serummarkers
providing useful support of the diagnosis of malignancy when
elevated, but with significant risk of producing false negatives.
Carcinoembryonic antigen (CEA) can be expected to be raised in
62%of cases of colorectal livermetastases and cancer antigen (CA)
19-9 is likely to be elevated in just 40%.42 The choice of imaging
modality must be tailored to individual circumstances in terms
of local expertise and likely underlying diagnosis. MRI seems to
confer the greatest degree of sensitivity and specificity.41,43 All tech-
niques remain extremely operator-dependent, however, and it is
important that resectable lesions are investigated in high-volume
specialist units by an established protocol. The final decision
regarding treatment, whether by resection or not, may then be
decided by an appropriate multidisciplinary team.
Detection and diagnosis of liver metastases
Metastatic liver disease is usually detected either as part of a
focused surveillance programme following resection of a primary
tumour (most often of colorectal origin) or else as a de novo
presentation with a previously undiagnosed primary. In both
groups the initial imaging modality is usually either CT or ultra-
sonography; respective levels of sensitivity and specificity of 40%
and 63% for ultrasound and 89% and 89% for CT have been
reported.44 Although clear guidelines for follow-up are yet to be
decided, CT is to be favoured for cancer surveillance,45 with
routine CEA measurement adding respective sensitivity and
specificity of 80% and 86% following resection of a colorectal
primary46 and similar sensitivity of 79% for Ca15-3 in breast
cancer.47
Following detection, MRI offers the greatest accuracy in terms
of characterization and definitive diagnosis.41 In addition, there is
clinical research interest in contrast ultrasound and an emerging
role for 18F-FDG positron emission tomography (PET) CT.
Magnetic resonance techniques for the
characterization of liver metastases
Magnetic resonance imaging has consistently been shown to be
more specific for diagnosing metastatic liver disease than both
ultrasound and CT and is considered by most units as the refer-
ence method for preoperative evaluation of resectable disease.48–52
Issues relating to the resolution of small lesions of <1 cm have
been resolved to a degree by advances in technological aspects,
image phasing and weighting and the use of contrast agents,
with a result that lesions >5 mm can now be accurately
characterized.41,53–56
Despite these advances, MRI remains highly operator-
dependant and scans must be optimally planned to maximize
their value. This will allow maximum exploitation of the various
benefits to be attained by combining weighting and phase of scan-
ning, along with the use of contrast agents.
Unenhanced sequences will give important information on
fluid composition, with T2 weighting distinguishing solid from
fluid-filled lesions41 (Fig. 2). In- and out-of-phase (chemical shift)
imaging with T1 weighting will allow the differentiation of solid
lesions from focal fatty changes as a result of the reduced signal
intensity on out-of-phase images from fatty liver.57
The addition of contrast agents has enabled the characteriza-
tion of sub-centimetre lesions58 and there are a variety of agents in
clinical use. Each agent demonstrates specific properties, which
can be used to distinguish small lesions from the background
parenchyma, and relies on modern hardware to provide suffi-
ciently thin slices to detect such lesions. Dual contrast imaging is
optimal for the characterization of focal liver lesions, whereby a
combination of agents that will accumulate in both the extracel-
lular fluid and within the liver cells themselves is used. Differing
characteristics in uptake by the various lesions will thus facilitate
differentiation.
Gadolinium accumulates in the extracellular space and will
delineate hypervascular lesions in the arterial phase, which exhibit
rapid accumulation of contrast41 which can be compared with
slower uptake by the background normal parenchyma. This
contrast is also useful for detecting smaller surface lesions, which
become apparent on delayed images with suppression of the sur-
rounding fat of both the background parenchyma and adjacent
abdominal wall59 (Fig. 2).
Simple cysts can be classically differentiated by their non-
progressive enhancement and haemangiomata by centripetal dis-
continuous and progressive enhancement.
Liver-specific contrast agents have also been developed. These
will target either hepatocytes, producing positive enhancement
of normal parenchyma on T1 images (such as gadobente or
mangafodipir) or Kuppfer cells, (the supermagnetic iron oxide
[SPIO] agents), producing signal loss on T2 images. Malignant
liver lesions lack the presence of functioning hepatocytes; these
agents allow the differentiation of tumours that otherwise
possess similar gadolinium perfusion characteristics to normal
liver.
Gadobenate and gadoxetic acid have the extra utility of a bipha-
sic enhancement profile in that they behave like extracellular
gadolinium in the early phase and become liver-specific in later
phases. The timing of image acquisition is therefore of essential
importance and is specific to the contrast agent being used.
The differential uptake of contrast by normal liver and solid
lesions has resulted in improved resolution of small lesions with
liver-specific MRI compared with unenhanced MRI, gadolinium-
enhanced MRI and contrast CT,48,50,52,55 particularly with lesions
>1 cm60 (Fig. 2).
Lesions develop progressively from microscopic deposits and
inevitably there will be a limit to the resolution at which a positive
diagnosis can be made. Given that the current limit is set as low as
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5 mm, an expectant approach with interval scanning remains a
safe compromise for the characterization of lesions <5 mm in size
and has a negligible potential impact on outcome.
Contrast ultrasound for detection of liver
metastases
Contrast ultrasound is advantaged by having no radiation dose
compared with CT and is relatively quick to perform compared
with a full MRI assessment. The use of micro-bubble contrast has
been shown to increase the sensitivity of plain ultrasound from
60% to 82%.61
18F-FDG PET CT
Owing to the high background metabolic activity of the liver,
PET CT can be difficult to interpret and the majority of studies
suggest that MRI remains more sensitive for the characterization
of intrahepatic lesions.62 There is certainly an emerging role for
PET CT, however, particularly in the detection of extrahepatic
disease in non-colorectal liver metastases from primary tumours
that are known to commonly metastasize to other sites, such as
renal, breast and ovarian carcinoma and malignant melanoma. It
is also the senior author’s practice to use PET CT preoperatively
in cases of colorectal liver metastases with poor prognoses or
where resection would be especially challenging. PET CT can be
expected to detect extrahepatic disease that is not detected on
contrast-enhanced CT, which can change the surgical approach
in patients with colorectal liver metastases in up to 17% of
cases.63 As it becomes more widely available, its role in the pre-
operative staging of extrahepatic disease can be expected to
expand.
Preoperative imaging for hepatocellular
carcinoma
Magnetic resonance imaging again represents the reference stan-
dard among tests for the characterization of HCC; a meta-analysis
has suggested sensitivity and specificity of 81% and 85%, respec-
tively, which exceed the reported equivalents of both ultrasound
(60% and 97%) and CT (68% and 93%).43 The costs and time
required for full liver protocol scanning, however, currently pro-
hibit the use of MRI as a screening tool and concerns regarding
repeated doses of radiation have resulted in the widespread use of
ultrasound with serum AFP (alpha-fetoprotein) level for routine
surveillance. An AFP level >400 ng/ml is generally accepted as a
diagnostic cut-off, although it is recognized that around 30%
of HCC measuring <4 cm are not expected to have an AFP
< 200 ng/ml and that up to 20% of HCCs do not produce AFP,
irrespective of their size.64
Targeted MRI characterization of nodules in known cirrhotics
is therefore advocated65 and has been shown to justify surgical
Figure 2 Images obtained by computed tomography (CT) with venous contrast, T2-weighted HASTE magnetic resonance imaging (MRI),
gadolinium-enhanced MRI and resovist-enhanced MRI. The comparative images show a simple cyst in segment 4b (CT and GAD images),
displaying a typically high signal on T2 images and a metastasis in segment 2 (HASTE and resovist images). Gadolinium, which is an
extracellular contrast agent, produces a typical ‘ring-enhancement’ of metastases, whereas resovist, which is a liver-specific agent, reduces
the signal from normal parenchyma, which leads to a relatively increased signal from the metastasis
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treatment, whether by resection or transplantation, on the basis
of radiological appearance alone and without recourse to
biopsy.40,66,67
Conclusions
Biopsy of resectable liver malignancies, whether primary or sec-
ondary tumours, has been shown to be associated with signifi-
cant risk for both mechanical and oncological complications.
In both groups, preoperative biopsy is associated with a poorer
longterm outcome. Advances in imaging techniques have per-
mitted preoperative characterization of solid lesions with a
diagnostic accuracy equivalent to or greater than that of tissue
biopsy and a maximum reported accuracy of 97.9% in a com-
bination of contrast ultrasound, CT and MRI.68 In cases of true
diagnostic uncertainty with small lesions, we would advocate a
‘trial of time’ with early interval surveillance.
Primary surgical treatment, whether by resection or transplan-
tation, has been well described and safely performed on the basis
of non-invasive investigation alone, with a minimal false-positive
rate in the resected specimen.
As chemotherapeutic advances allowing downstaging,69 staged
liver resections and portal vein embolization70 all permit resection
of what would hitherto have been considered as inoperable
disease, the role of biopsy shrinks even further and should not be
performed without specialist MDT discussion.
Preoperative biopsy is therefore not only unnecessary, but
damages the longterm outcome for patients with resectable
disease and must be strongly discouraged. Specialist units offering
surgical treatment will have access to the necessary imaging
modalities and therefore solid liver lesions should be referred for
tertiary assessment prior to biopsy.
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